Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

P Koehler, M Bassetti, A Chakrabarti… - The Lancet Infectious …, 2021 - thelancet.com
Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway
epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary …

The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections

J Machhi, J Herskovitz, AM Senan, D Dutta… - Journal of neuroimmune …, 2020 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of
coronavirus disease 2019 (COVID-19). SARS-CoV-2, is a positive-sense single-stranded …

Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2020 - academic.oup.com
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies

HF Tsang, LWC Chan, WCS Cho, ACS Yu… - Expert review of anti …, 2021 - Taylor & Francis
Introduction To date, the transmission of Coronavirus Disease-2019 (COVID-19) is still
uncontrollable with the fact that the numbers of confirmed and death cases are still …

A review: Mechanism of action of antiviral drugs

S Kausar, F Said Khan… - International journal …, 2021 - journals.sagepub.com
Antiviral drugs are a class of medicines particularly used for the treatment of viral infections.
Drugs that combat viral infections are called antiviral drugs. Viruses are among the major …

Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency

T Acter, N Uddin, J Das, A Akhter, TR Choudhury… - Science of the Total …, 2020 - Elsevier
According to data compiled by researchers at Johns Hopkins University in Baltimore,
Maryland, more than two and half million cases of coronavirus disease 2019 (COVID-19) …

[HTML][HTML] Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

S Arshad, P Kilgore, ZS Chaudhry, G Jacobsen… - International journal of …, 2020 - Elsevier
Abstract Significance The United States is in an acceleration phase of the COVID-19
pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS …

Early short-course corticosteroids in hospitalized patients with COVID-19

R Fadel, AR Morrison, A Vahia, ZR Smith… - Clinical Infectious …, 2020 - academic.oup.com
Background There is no proven antiviral or immunomodulatory therapy for coronavirus
disease 2019 (COVID-19). The disease progression associated with the proinflammatory …

Antiviral treatment of COVID-19

S Yavuz, S Ünal - Turkish journal of medical sciences, 2020 - journals.tubitak.gov.tr
Currently, there is not any specific effective antiviral treatment for COVID-19. Although most
of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe …

COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation

D Kempuraj, GP Selvakumar, ME Ahmed… - The …, 2020 - journals.sagepub.com
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) is a new pandemic infectious disease that originated in China …